|
|
 Previous Article | Table of Contents | Next Article 
Long-term follow-up of patients with invasive fungal disease who received
adjunctive therapy with recombinant human macrophage colony- stimulating
factor
J Nemunaitis, K Shannon-Dorcy, FR Appelbaum, J Meyers, A Owens, R Day, D Ando, C O'Neill, D Buckner and J Singer
Fred Hutchinson Cancer Research Center, Seattle, WA.
Mortality of bone marrow transplant (BMT) patients who develop invasive
fungal infection is greater than 80%. Long-term follow-up of 46 consecutive
BMT patients who received recombinant human macrophage colony-stimulating
factor (rhM-CSF) as adjunctive therapy with standard antifungal treatment
who were entered into phase I/II trials at The Fred Hutchinson Cancer
Research Center is reported. rhM-CSF (100 micrograms/m2 to 2,000
micrograms/m2; Chiron/Cetus Corporation, Emeryville, CA) was administered
from day 0 to 28 after determination of progressive fungal disease. Results
of long-term follow-up of fungal infection, relapse, and survival were
compared with 58 similar historical controls. Multivariable analysis of the
patients who received rhM-CSF showed two factors that significantly
correlated with poor survival: Karnofsky score < or = 20% and
Aspergillus infection. Overall, survival of patients who received rhM-CSF
was greater than that of historical patients (27% v 5%) and was entirely
because of a 50% survival rate in patients with Candida infection and
Karnofsky scores greater than 20%. Prospective, randomized, controlled
trials to determine efficiency of rhM-CSF are indicated and should be
directed at patients with invasive candidiasis.
Volume 82,
Issue 5,
pp. 1422-1427,
09/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Suzu, H. Harada, T. Matsumoto, and S. Okada
HIV-1 Nef interferes with M-CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities
Blood,
April 15, 2005;
105(8):
3230 - 3237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, P. B. Michelsen, and L. H. Bopp
Effects of Cytokines and Fluconazole on the Activity of Human Monocytes against Candida albicans
Antimicrob. Agents Chemother.,
January 1, 2001;
45(1):
96 - 104.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Reichenberger, J.M. Habicht, A. Gratwohl, and M. Tamm
Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients
Eur. Respir. J.,
January 1, 2001;
19(4):
743 - 755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kuhara, K. Uchida, and H. Yamaguchi
Therapeutic Efficacy of Human Macrophage Colony-Stimulating Factor, Used Alone and in Combination with Antifungal Agents, in Mice with Systemic Candida albicans Infection
Antimicrob. Agents Chemother.,
January 1, 2000;
44(1):
19 - 23.
[Abstract]
[Full Text]
|
|
|
|
|
